Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Mar 25, 2024 (filed on Mar 27, 2024)Insider Name:Davis Todd COwnership Type:Direct OwnershipSecurities:Non-Qualified Stock Option (right to buy)Nature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-2,156Price:--
-
Mar 25, 2024 (filed on Mar 27, 2024)Insider Name:Davis Todd COwnership Type:Direct OwnershipSecurities:Non-Qualified Stock Option (right to buy)Nature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-2,855Price:--
-
Mar 25, 2024 (filed on Mar 27, 2024)Insider Name:Davis Todd COwnership Type:Direct OwnershipSecurities:Non-Qualified Stock Option (right to buy)Nature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-3,556Price:--
-
Mar 25, 2024 (filed on Mar 27, 2024)Insider Name:Davis Todd COwnership Type:Direct OwnershipSecurities:Non-Qualified Stock Option (right to buy)Nature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-7,448Price:--
-
Mar 25, 2024 (filed on Mar 27, 2024)Insider Name:Davis Todd COwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:3,556Price:$66.19
-
Mar 25, 2024 (filed on Mar 27, 2024)Insider Name:Davis Todd COwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:2,156Price:$68.51
-
Mar 25, 2024 (filed on Mar 27, 2024)Insider Name:Davis Todd COwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:2,855Price:$67.24
-
Mar 25, 2024 (filed on Mar 27, 2024)Insider Name:Davis Todd COwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:7,448Price:$46.20
-
Mar 05, 2024 (filed on Mar 06, 2024)Insider Name:Aryeh JasonOwnership Type:Direct OwnershipSecurities:Non-Qualified Stock Option (right to buy)Nature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-2,893Price:--
-
Mar 05, 2024 (filed on Mar 06, 2024)Insider Name:Aryeh JasonOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:2,893Price:$39.35
Filings by filing date
-
Mar 25, 2024 (filed on Mar 27, 2024)Insider Name:Davis Todd COwnership Type:Direct OwnershipSecurities:Non-Qualified Stock Option (right to buy)Nature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-2,156Price:--
-
Mar 25, 2024 (filed on Mar 27, 2024)Insider Name:Davis Todd COwnership Type:Direct OwnershipSecurities:Non-Qualified Stock Option (right to buy)Nature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-2,855Price:--
-
Mar 25, 2024 (filed on Mar 27, 2024)Insider Name:Davis Todd COwnership Type:Direct OwnershipSecurities:Non-Qualified Stock Option (right to buy)Nature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-3,556Price:--
-
Mar 25, 2024 (filed on Mar 27, 2024)Insider Name:Davis Todd COwnership Type:Direct OwnershipSecurities:Non-Qualified Stock Option (right to buy)Nature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-7,448Price:--
-
Mar 25, 2024 (filed on Mar 27, 2024)Insider Name:Davis Todd COwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:3,556Price:$66.19
-
Mar 25, 2024 (filed on Mar 27, 2024)Insider Name:Davis Todd COwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:2,156Price:$68.51
-
Mar 25, 2024 (filed on Mar 27, 2024)Insider Name:Davis Todd COwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:2,855Price:$67.24
-
Mar 25, 2024 (filed on Mar 27, 2024)Insider Name:Davis Todd COwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:7,448Price:$46.20
-
Mar 05, 2024 (filed on Mar 07, 2024)Insider Name:Sabba Stephen LOwnership Type:Direct OwnershipSecurities:Non-Qualified Stock Option (right to buy)Nature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-2,893Price:--
-
Mar 05, 2024 (filed on Mar 07, 2024)Insider Name:Sabba Stephen LOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-1,893Price:$74.30
News
Biz Brief
Sector: Healthcare | Industry: Pharmaceuticals |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 555 Heritage Drive, Suite 200 JUPITER FL 33458 |
Tel: | N/A |
Website: | https://www.ligand.com |
IR: | See website |
Key People | ||
Matthew Edward Korenberg President, Chief Operating Officer | Todd C. Davis Chief Executive Officer, Director | Octavio Espinoza Chief Financial Officer | Andrew Reardon Chief Legal Officer |
Business Overview |
Ligand Pharmaceuticals Incorporated is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of medicines. The Company does this by providing financing, licensing its technologies or both. Its Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. This technology has enabled several United States Food and Drug Administration (FDA)-approved products, including Gilead's Veklury, Amgen's Kyprolis, Baxter International's Nexterone, Melinta Therapeutics' Baxdela and Sage Therapeutics' Zulresso. Its technologies also include HepDirect, LTP and BEPro Technology Platform, SUREtechnology Platform (owned by Selexis), and Pelican Expression Technology. It has established multiple alliances, licenses and other business relationships with various pharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences and Baxter International. |
Financial Overview |
For the fiscal year ended 31 December 2023, Ligand Pharmaceuticals Inc revenues decreased 33% to $131.3M. Net income before extraordinary items totaled $53.8M vs. loss of $5.2M. Revenues reflect Captisol segment decrease of 73% to $28.4M, Teriparatide injection segment decrease of 30% to $11.1M. Net Income reflects SBC - General and administrative expense decrease of 51% to $19.5M (expense). |
Employees: | 58 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $1,226M as of Dec 31, 2023 |
Annual revenue (TTM): | $131.31M as of Dec 31, 2023 |
EBITDA (TTM): | $46.34M as of Dec 31, 2023 |
Net annual income (TTM): | $53.82M as of Dec 31, 2023 |
Free cash flow (TTM): | -$14.68M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 17,705,287 as of Feb 26, 2024 |
Index Membership: | S&P 600 Small Cap |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |